Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations (Q37924648)

25 August 2017

7 references

13 March 2019

22 June 2019

17 June 2019

30 June 2019

20 November 2019

28 October 2020

19 July 2021

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations (English)

1 reference

non-steroidal anti-inflammatory drug

25 August 2017

6 references

13 March 2019

22 June 2019

17 June 2019

30 June 2019

20 November 2019

28 October 2020

1 reference

20 November 2019

1 reference

28 October 2020

anti-inflammatory agent

1 reference

19 July 2021

1 reference

5

Jonas Fransson

1 reference

25 August 2017

Christina Kaiser

1

1 reference

25 August 2017

Ann Knight

2

1 reference

25 August 2017

Dan Nordström

3

1 reference

25 August 2017

Tom Pettersson

4

1 reference

25 August 2017

Ebba Florin-Robertsson

6

1 reference

25 August 2017

Björn Pilström

7

1 reference

25 August 2017

language of work or name

1 reference

1 September 2011

1 reference

Rheumatology International

25 August 2017

1 February 2012

7 references

13 March 2019

22 June 2019

17 June 2019

30 June 2019

20 November 2019

28 October 2020

19 July 2021

8 references

25 August 2017

13 March 2019

22 June 2019

17 June 2019

30 June 2019

20 November 2019

28 October 2020

19 July 2021

32

1 reference

25 August 2017

2

1 reference

25 August 2017

295-299

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

25 August 2017

1 reference

Mechanisms of adverse drug reactions to biologics

19 July 2021

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Certolizumab pegol for the management of Crohn's disease in adults

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Anakinra for rheumatoid arthritis: a systematic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Mast cells and eosinophils: the two key effector cells in allergic inflammation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Addressing the safety of anakinra in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Antiallergic anti-inflammatory effects of H1-antihistamines in humans.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Physiologic role of interleukin-1 receptor antagonist

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Review of excipients and pH's for parenteral products used in the United States.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Pain perception after subcutaneous injections of media containing different buffers

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Mast cell mediators in citric acid-induced airway constriction of guinea pigs

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Anion binding and controlled aggregation of human interleukin-1 receptor antagonist

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264859

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 September 2018

1 reference

12 December 2020

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

12 December 2020

Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection

1 reference

12 December 2020

Local tolerance of subcutaneous injections

1 reference

12 December 2020

Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study

1 reference

12 December 2020

10.1007/S00296-011-2096-3

Identifiers

DOI

1 reference

release_dndojp7rvfdtdmbpwb7v7ilz44

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dndojp7rvfdtdmbpwb7v7ilz44

24 November 2022

mapped directly with Wikidata item

1 reference

25 August 2017

PubMed publication ID

21881988

1 reference